四种SARS-CoV-2分子体外诊断试剂在鼻咽拭子中的比较
该研究评估了四种获FDA紧急使用授权的SARS-CoV-2分子诊断试剂的分析灵敏度和临床表现,标本为有症状患者的鼻咽拭子。评估的试剂包括改良CDC实时RT-PCR、Simplexa COVID-19 Direct、GenMark ePlex SARS-CoV-2和Hologic Panther Fusion SARS-CoV-2。研究指出,准确的分子诊断对识别COVID-19阳性患者和支持感染控制至关重要,结果有助于实验室和临床团队选择检测平台。
要点
- 评估四种获FDA紧急使用授权的SARS-CoV-2分子检测试剂的分析灵敏度和临床表现。
- 标本为有症状患者的鼻咽拭子,采用实时RT-PCR等方法进行检测。
- 检测平台的选择需结合实验室条件与临床需求,原文结果可供参考。
核心结论
- 研究比较了四种SARS-CoV-2分子诊断试剂在鼻咽拭子中的分析灵敏度和临床表现,为实验室选择检测平台提供依据。
研究设计与样本
- 研究评估四种获FDA紧急使用授权的SARS-CoV-2分子诊断试剂,标本为有症状患者的鼻咽拭子。
临床怎么用
- 实验室和临床团队可依据该比较信息决定实施哪种SARS-CoV-2分子检测平台。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly nonspecific, and symptoms overlap those of other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19-positive patients. In the present study, we evaluated the analytical sensitivity and clinical performance of the following four SARS-CoV-2 molecular diagnostic assays granted emergency use authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (modified CDC) assay, the Simplexa COVID-19 Direct (Diasorin Molecular) assay, GenMark ePlex SARS-CoV-2 (GenMark) assay, and the Hologic Panther Fusion SARS-CoV-2 (Hologic) assay. This information is crucial for both laboratories and clinical teams as decisions on which testing platform to implement are made.
引用
- Zhen W, Manji R, Smith E, et al. Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens. J Clin Microbiol. 2020. PMID: 32341143. doi:10.1128/JCM.00743-20
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。